pharma · Melanoma · Multiple Myeloma · RNA
Atrium Therapeutics
Atrium Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 10578 Science Center Dr, Suite 125, San Diego, California 92121, US
- Founded
- 2026
- Employees
- 46
- Programs
- 31
- Drugs
- 33
- Patents
- 37
Atrium Therapeutics projects
5 ClinicalTrials.gov programs sponsored by Atrium Therapeutics.
Atrium Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
IVAC MUTANOME, RBL001/RBL002
Atrium Therapeutics
Melanoma
1 trial -
Nivolumab
Atrium Therapeutics
Brain and Nervous System
1 trial -
Novel Supplement Based Therapy
Atrium Therapeutics
Small Intestinal Bacterial Overgrowth
1 trial -
RBL001/RBL002
Atrium Therapeutics
Melanoma
1 trial -
SAR441000
Atrium Therapeutics
Metastatic Neoplasm
1 trial
Frequently asked questions
How many clinical projects does Atrium Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.